DK1036065T3 - Substituerede imidazolderivater med agonistlignende aktivitet ved alfa-2B- eller 2B/2C-adrenerge receptorer - Google Patents

Substituerede imidazolderivater med agonistlignende aktivitet ved alfa-2B- eller 2B/2C-adrenerge receptorer

Info

Publication number
DK1036065T3
DK1036065T3 DK98962883T DK98962883T DK1036065T3 DK 1036065 T3 DK1036065 T3 DK 1036065T3 DK 98962883 T DK98962883 T DK 98962883T DK 98962883 T DK98962883 T DK 98962883T DK 1036065 T3 DK1036065 T3 DK 1036065T3
Authority
DK
Denmark
Prior art keywords
agonist
alpha
activity
adrenergic receptors
imidazole derivatives
Prior art date
Application number
DK98962883T
Other languages
Danish (da)
English (en)
Inventor
Ken Chow
Daniel W Gil
Dale A Harcourt
Michael E Garst
Larry A Wheeler
Stephen A Munk
James A Burke
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DK1036065T3 publication Critical patent/DK1036065T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/28—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK98962883T 1997-12-04 1998-12-03 Substituerede imidazolderivater med agonistlignende aktivitet ved alfa-2B- eller 2B/2C-adrenerge receptorer DK1036065T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98534797A 1997-12-04 1997-12-04

Publications (1)

Publication Number Publication Date
DK1036065T3 true DK1036065T3 (da) 2004-08-30

Family

ID=25531403

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98962883T DK1036065T3 (da) 1997-12-04 1998-12-03 Substituerede imidazolderivater med agonistlignende aktivitet ved alfa-2B- eller 2B/2C-adrenerge receptorer

Country Status (22)

Country Link
EP (2) EP1036065B1 (de)
JP (3) JP4783502B2 (de)
KR (1) KR100544787B1 (de)
CN (1) CN1284066A (de)
AR (1) AR017807A1 (de)
AT (1) ATE266643T1 (de)
AU (1) AU744798B2 (de)
BR (1) BR9813381A (de)
CA (1) CA2312334A1 (de)
DE (1) DE69823868T2 (de)
DK (1) DK1036065T3 (de)
ES (1) ES2216339T3 (de)
HU (1) HUP0004557A3 (de)
IL (2) IL136388A0 (de)
NO (2) NO317292B1 (de)
NZ (1) NZ504667A (de)
PL (1) PL341009A1 (de)
PT (1) PT1036065E (de)
RU (1) RU2235092C2 (de)
SK (1) SK8542000A3 (de)
TW (1) TW577878B (de)
WO (1) WO1999028300A1 (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4783502B2 (ja) * 1997-12-04 2011-09-28 アラーガン、インコーポレイテッド α２Ｂまたは２Ｂ／２Ｃアドレナリン受容体において作動剤様活性を示す置換イミダゾール誘導体
AU2002254265B2 (en) * 1997-12-04 2008-05-15 Allergan, Inc. Imidiazole derivatives and their use as agonists selective at alpha 2B or 2B/2C adrenergic receptors
US6841684B2 (en) * 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
TWI283669B (en) * 1999-06-10 2007-07-11 Allergan Inc Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors
US6388090B2 (en) 2000-01-14 2002-05-14 Orion Corporation Imidazole derivatives
FI20000073A0 (fi) * 2000-01-14 2000-01-14 Orion Yhtymae Oy Uusia imidatsolijohdannaisia
US6294553B1 (en) * 2000-02-15 2001-09-25 Allergan Sales, Inc. Method for treating ocular pain
US6593324B2 (en) 2000-03-01 2003-07-15 Orion Corporation Dervatives of quinoline as alpha-2 antagonists
JP2006036636A (ja) * 2000-11-22 2006-02-09 Nippon Shinyaku Co Ltd 消化管機能障害治療剤及びスクリーニング方法
FR2825926A1 (fr) * 2001-06-14 2002-12-20 Sod Conseils Rech Applic Derives d'imidazoles modulant les canaux sodiques
EA008537B1 (ru) 2002-04-03 2007-06-29 Орион Корпорейшн Полициклические соединения как эффективные антагонисты альфа2-адренорецептора
AU2003235310A1 (en) * 2002-04-22 2003-11-03 Takeda Chemical Industries, Ltd. Novel screening method
US7276522B2 (en) 2002-05-21 2007-10-02 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7345065B2 (en) * 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
US7358269B2 (en) 2002-05-21 2008-04-15 Allergan, Inc. 2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one
US7323485B2 (en) 2002-05-21 2008-01-29 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7091232B2 (en) 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
JP2006504741A (ja) * 2002-10-08 2006-02-09 アラーガン、インコーポレイテッド 痴呆およびパーキンソン病の処置における（２−イミダゾリン−２−イルアミノ）キノキサリンの使用方法
DE60327335D1 (de) * 2002-10-08 2009-06-04 Allergan Inc Alpha 2b oder 2b/2c adrenozeptor-agonisten zur behandlung von morbus alzheimer und morbus parkinson
US7141597B2 (en) * 2003-09-12 2006-11-28 Allergan, Inc. Nonsedating α-2 agonists
ATE514700T1 (de) 2004-09-20 2011-07-15 Janssen Pharmaceutica Nv Neues tetrazyklisches heteroatom mit als sexualsteroidhormon-rezeptormodulatoren geeigneten derivaten
PT1796664E (pt) 2004-09-20 2014-02-14 Janssen Pharmaceutica Nv Novos derivados tetracíclicos contendo hetoroátomos úteis como moduladores do receptor da hormona esteroide sexual
NZ553341A (en) * 2004-09-24 2010-11-26 Allergan Inc 4-(phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists
WO2006036507A1 (en) 2004-09-24 2006-04-06 Allergan, Inc. 4-(heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists
NZ553290A (en) 2004-09-24 2010-11-26 Allergan Inc 4-(condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists
BRPI0516217A (pt) * 2004-09-28 2008-08-26 Allergan Inc compostos de 4-benzil-1,3-diidro-imidazol-2-tionas não-substituìdos e substituìdos que atuam como agonistas especìficos ou seletivos alfa2-adrenérgicos e métodos de utilização dos mesmos
US7390829B2 (en) 2005-06-29 2008-06-24 Allergan, Inc. Alpha-2 adrenergic agonists
US7700592B2 (en) 2005-08-25 2010-04-20 Schering Corporation α2C adrenoreceptor agonists
RU2008110902A (ru) 2005-08-25 2009-09-27 Шеринг Корпорейшн (US) Агонисты адренорецепторов альфа а2с
US7592362B2 (en) 2006-01-19 2009-09-22 Pfizer Limited Substituted imidazoles
WO2007085556A2 (en) 2006-01-27 2007-08-02 F. Hoffmann-La Roche Ag Use of 4-imidazole derivatives for cns disorders
EP2013202B1 (de) * 2006-04-20 2010-06-16 Janssen Pharmaceutica N.V. Substituierte pyrazinonderivate zur verwendung als arzneimittel
RU2008150485A (ru) * 2006-05-22 2010-06-27 Янссен Фармацевтика Н.В. (Be) Замещенные производные пиразинона для применения в качестве лекарственного средства
AU2007312390B2 (en) 2006-10-19 2013-03-28 F. Hoffmann-La Roche Ag Aminomethyl-4-imidazoles
CA2668454A1 (en) 2006-11-02 2008-05-08 F. Hoffmann-La Roche Ag Substituted 2-imidazoles
WO2008058867A2 (en) * 2006-11-16 2008-05-22 F. Hoffmann-La Roche Ag Substituted 4-imidazoles
CN101190218B (zh) * 2006-11-20 2010-12-22 四川科瑞德制药有限公司 替扎尼定及其衍生物在制备抗焦虑症药物中的用途
ES2364701T3 (es) 2006-12-13 2011-09-12 F. Hoffmann-La Roche Ag Nuevos 2-imidazoles como ligandos para receptores asociados a aminas trazas.
US20080146523A1 (en) 2006-12-18 2008-06-19 Guido Galley Imidazole derivatives
WO2008088936A1 (en) * 2007-01-12 2008-07-24 Allergan, Inc. Quinolynylmethylimidizoles as therapeutic agents
WO2008086131A1 (en) 2007-01-12 2008-07-17 Allergan, Inc. Naphthylmethylimidizoles as therapeutic agents
US8119807B2 (en) 2007-01-12 2012-02-21 Allergan, Inc. Quinolynylmethylimidizoles as therapeutic agents
EP2114906B1 (de) 2007-02-02 2014-08-06 F. Hoffmann-La Roche AG 2-aminooxazolinverbindungen als taar1-liganden für erkrankungen des zentralen nervensystems
MX2009008777A (es) 2007-02-13 2009-08-25 Schering Corp Derivados y analogos de cromano como agonistas de los receptores alfa2c adrenergicos funcionalmente selectivos.
WO2008100480A1 (en) 2007-02-13 2008-08-21 Schering Corporation Functionally selective alpha2c adrenoreceptor agonists
EP2125749A2 (de) 2007-02-13 2009-12-02 Schering Corporation Funktional selektive alpha2c-adrenorezeptor-agonisten
CA2676944C (en) 2007-02-15 2016-01-19 F. Hoffmann-La Roche Ag 2-aminooxazolines as taar1 ligands
AU2008256928A1 (en) * 2007-05-23 2008-12-04 Allergan, Inc. Therapeutic ((phenyl)imidazolyl)methylquinolinyl compounds
CN101318020B (zh) * 2007-06-06 2011-09-28 四川科瑞德制药有限公司 抗焦虑或/和抗抑郁的药物组合物及用途
WO2009003868A2 (en) 2007-07-02 2009-01-08 F. Hoffmann-La Roche Ag 2 -imidazolines having a good affinity to the trace amine associated receptors (taars)
AU2008270444A1 (en) 2007-07-03 2009-01-08 F. Hoffmann-La Roche Ag 4-imidazolines and their use as antidepressants
CN101778628B (zh) * 2007-07-17 2013-02-06 阿勒根公司 治疗焦虑的方法
TWI457122B (zh) 2007-07-20 2014-10-21 Orion Corp 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3－二氫苯並[1,4]戴奧辛－2－基甲基衍生物
CA2694362A1 (en) 2007-07-27 2009-02-05 F. Hoffmann-La Roche Ag 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as taar-ligands
AU2008285795A1 (en) 2007-08-03 2009-02-12 F. Hoffmann-La Roche Ag Pyridinecarboxamide and benzamide derivatives as TAAR1 ligands
WO2009020578A1 (en) * 2007-08-06 2009-02-12 Schering Corporation Alpha2c adrenoreceptor agonists
US7902247B2 (en) 2008-01-09 2011-03-08 Allergan, Inc. Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
AU2009205539B2 (en) * 2008-01-18 2013-12-05 Allergan.Inc Substitued-aryl-(imidazole)-methyl)-phenyl compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
WO2009105504A2 (en) 2008-02-21 2009-08-27 Schering Corporation Functionally selective alpha2c adrenoreceptor agonists
AU2009246601A1 (en) * 2008-05-13 2009-11-19 Allergan, Inc. Quinolynylmethylimidizoles as therapeutic agents
DE102008001932A1 (de) 2008-05-21 2009-11-26 Bayer Cropscience Ag Substiuierte Spiroisoxazoline
US8242153B2 (en) 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
EP2356106A1 (de) 2008-10-07 2011-08-17 Schering Corporation Biarylspiroaminooxazolinanaloga als modu modulatoren des alpha2c-adrenergen rezeptors
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
KR102050187B1 (ko) * 2010-11-16 2019-11-28 알러간, 인코포레이티드 (3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐)메탄올을 포함하는 약제학적 조성물
US9073911B2 (en) 2011-06-09 2015-07-07 Hoffmann-La Roche Inc. Pyrazole derivatives
US9029370B2 (en) 2011-06-10 2015-05-12 Hoffmann-La Roche Inc. Substituted benzamide derivatives
EP2782569A1 (de) 2011-11-21 2014-10-01 Allergan, Inc. Pharmazeutische zusammensetzungen mit 4-[1-(2,3-dimethylphenyl-)ethyl-]3h-imidazolderivaten zur behandlung von netzhauterkrankungen
AR090557A1 (es) * 2012-04-02 2014-11-19 Orion Corp DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2
WO2017157873A1 (en) 2016-03-17 2017-09-21 F. Hoffmann-La Roche Ag 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar
CN110240542B (zh) * 2019-06-24 2020-05-12 牡丹江医学院 一种选择性β1-肾上腺素受体抑制剂及其在制备心血管疾病药物中的用途
KR20240089748A (ko) * 2021-10-20 2024-06-20 어셈블리 바이오사이언시스, 인크. 방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU85747A1 (fr) * 1985-01-28 1986-08-04 Continental Pharma Derives d'imidazole leur preparation et utilisation ainsi que les compositions pharmaceutiques contenant des derives
FI864570A0 (fi) * 1986-11-11 1986-11-11 Farmos Oy Terapeutiskt anvaendbar foerening.
US4882343A (en) * 1987-08-28 1989-11-21 G. D. Searle & Co. Biarylalkylimidazole derivatives as anti-depressants
JPH01242571A (ja) * 1988-03-22 1989-09-27 Mitsui Petrochem Ind Ltd イミダゾール誘導体の製造方法
GB8823980D0 (en) * 1988-10-13 1988-11-23 Glaxo Group Ltd Chemical compounds
DE69212164T2 (de) * 1991-12-18 1996-12-05 Schering Corp., Kenilworth, N.J. Imidolylalkyl-derivate substituiert mit einem stickstoffenthaltende-6 gliedrigen ring
WO1994007866A1 (fr) * 1992-10-06 1994-04-14 Tokyo Tanabe Company Limited Inhibiteur d'aromatase
AU715350B2 (en) * 1995-05-12 2000-01-20 Allergan, Inc. Aryl-imidazolines and aryl-imidazoles useful as alpha-2 adrenergic agonists without cardiovascular side effects
GB9520150D0 (en) * 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
US5750720A (en) * 1996-03-28 1998-05-12 Ortho Pharmaceutical Corporation 4- (thien-3-yl)methyl!-imidazole analgesics
US5621113A (en) * 1996-03-28 1997-04-15 Ortho Pharmaceutical Corporation 4-[(thien-2-yl)methyl]-imidazole analgesics
US6841684B2 (en) * 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
JP4783502B2 (ja) * 1997-12-04 2011-09-28 アラーガン、インコーポレイテッド α２Ｂまたは２Ｂ／２Ｃアドレナリン受容体において作動剤様活性を示す置換イミダゾール誘導体

Also Published As

Publication number Publication date
ES2216339T3 (es) 2004-10-16
AU1802599A (en) 1999-06-16
NO20002773D0 (no) 2000-05-30
ATE266643T1 (de) 2004-05-15
KR100544787B1 (ko) 2006-01-23
EP1413576A2 (de) 2004-04-28
NO20035490D0 (no) 2003-12-10
JP2014012724A (ja) 2014-01-23
IL136388A0 (en) 2001-06-14
CN1284066A (zh) 2001-02-14
DE69823868D1 (de) 2004-06-17
NO317292B1 (no) 2004-10-04
BR9813381A (pt) 2000-10-03
NO20002773L (no) 2000-08-02
TW577878B (en) 2004-03-01
CA2312334A1 (en) 1999-06-10
SK8542000A3 (en) 2001-03-12
AU744798B2 (en) 2002-03-07
JP4783502B2 (ja) 2011-09-28
JP2010209111A (ja) 2010-09-24
DE69823868T2 (de) 2005-04-21
PT1036065E (pt) 2004-09-30
RU2235092C2 (ru) 2004-08-27
HUP0004557A3 (en) 2002-03-28
EP1036065A1 (de) 2000-09-20
NZ504667A (en) 2003-03-28
KR20010032776A (ko) 2001-04-25
AR017807A1 (es) 2001-10-24
WO1999028300A1 (en) 1999-06-10
PL341009A1 (en) 2001-03-12
HUP0004557A2 (hu) 2002-02-28
JP2001524542A (ja) 2001-12-04
EP1413576A3 (de) 2004-09-01
IL136388A (en) 2006-12-31
EP1036065B1 (de) 2004-05-12

Similar Documents

Publication Publication Date Title
DK1036065T3 (da) Substituerede imidazolderivater med agonistlignende aktivitet ved alfa-2B- eller 2B/2C-adrenerge receptorer
ITMI991964A0 (it) Derivati benzimidazolonici aventi affinita' mista per i recettori di s erotonina e dopamina
ATE246700T1 (de) Benzimidazolderivate
PT818454E (pt) Derivados de benzimidazole com actividade anti-histaminica
NO20011183L (no) 4,4-biarylpiperidinderivater med opoid reseptoraktivitet
PT900210E (pt) Derivados azahexano heterociclicos com actividade antviral
ID23385A (id) 4,5, diaril imidazol tersubstitutsi pada posisi 2
NO20004787D0 (no) Indolderivater med antiviral aktivitet
DE69921124D1 (de) Imidazolderivate und ihre verwendung als somatostatin rezeptorliganden
ID23168A (id) Reseptor anatagonis vitronektin
DK0924205T3 (da) Arylpiperaziner med aktivitet ved serotonin 1A-receptoren
PT1036072E (pt) Antagonistas de receptores de trombina
PT1027342E (pt) Derivados de ciclopentenos uteis como antagonistas do receptor da motilina
MA24632A1 (fr) Derives de 2-(4-aryl-ou heteroaryl-piperazine-1-ylmethyle)-1h- indole
DE69933135D1 (de) Benzimidazolderivate mit vitronectinrezeptor-antagonistischer wirkung
BR9707185A (pt) Nucleosídeos de benzimidazol modificados como agentes antivirais
BR9709982A (pt) Derivados de indolina úteis como antagonistas do receptor 5-ht-2c
BR9604831A (pt) Derivados de benzimidazol
ITMI991578A0 (it) Amidi e imidi cicliche dotate di attivita' antagonista selettiva per i l recettore adrenergico
ATE228514T1 (de) Indolin-derivate verwendbar als 5-ht-2c rezeptor- antagonisten
IT1290447B1 (it) Derivati 1,3-ossatiolanici ad attivita' antivirale
NO20004511L (no) Triazolderivater med antifungal aktivitet
DE69915835D1 (de) Imidazol-derivate
GB9902586D0 (en) Compounds having activity at imidazoline receptors
GB9815010D0 (en) Compounds having activity at imidazoline receptors